Galapagos, Idenix, Lentigen, Antisense Pharma, IDT | GenomeWeb

Galapagos, Idenix Ink Hepatitis and HIV Drug-Discovery Pact

Galapagos NV and Idenix Pharmaceuticals will collaborate on hepatitis and HIV infectious disease programs, Galapagos said last week.

Under the agreement, which is worth up to $2.5 million over two years, BioFocus, Galapagos' service division, will supply Idenix with its SoftFocus chemical compound collections. BioFocus will provide hit-to-lead and lead-optimization services.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.